ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2037

The Largest International Cohort Study of HA20 Reveals Novel Genetic Architecture and Age-Dependent Phenotypic Evolution

Manuel Carpio Tumba1, Tingyan He2, Jun Wang3, Elizabeth Kairis1, Kyr Goyette1, Akuti Kethri1, Urekha Karri4, Atif Towheed1, Jun Yang5, Qing Zhou6 and Daniella Schwartz1, 1University of Pittsburgh, Pittsburgh, PA, 2Shenzhen Children's Hospital, Shenzhen, China (People's Republic), 3Zhejiang University School of Medicine, Zhejiang, China (People's Republic), 4School of public health, Pittsburgh, PA, 5Rheumatology and Immunology Department of Shenzhen Children's Hospital, Shenzhen, 518100, China., Shenzhen, China (People's Republic), 6Zhejiang University School of Medicine, Hangzhou, China (People's Republic)

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Behçet's Syndrome, Cohort Study, genetics, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Haploinsufficiency of A20 (HA20) is a monogenic autoinflammatory disease caused by loss-of-function (LOF) mutations in TNFAIP3. HA20 was initially described as an early-onset form of Behçet’s disease (BD)1; however, subsequent reports have revealed a broad clinical picture that can also include features of autoimmunity, lymphoproliferation, immunodeficiency, and allergy. The initial clinical descriptions could have led to an inaccurate representation of the natural history due to reporting or ascertainment bias. This study is the first large multicenter cohort study describing the clinical spectrum, genetic landscape, and natural history of patients with HA20.

Methods: A retrospective analysis was conducted on HA20 patients referred to the study investigators following genetic testing that revealed a pathogenic or likely pathogenic variant in TNFAIP3. All variants were reviewed by study investigators in consultation with geneticists at participating sites. The diagnosis of HA20 was established through the identification of either a heterozygous TNFAIP3 pathogenic variant (ACMG PVS1) or a heterozygous deletion of 6q23 including TNFAIP3. Probands were identified using multigene panels, chromosomal microarrays, or next gen sequencing-based clinical assays. Some family members were diagnosed using single-gene TNFAIP3 testing after the initial proband diagnosis. Patients were divided into three groups (≤ 6 years, 6-16 years, and ≥ 16 years) for further analysis of the phenotype distribution.

Results: A total of 185 patients with HA20 from 41 rheumatology clinics across 7 countries were included. The median age at onset was 3.3 (range: 0.04-30). Detailed clinical records were available for 169 patients. Among them, 75 (44.4%) presented with an autoinflammation-predominant phenotype, 26 (15.4%) with an autoimmunity-predominant phenotype, and 56 (33.1%) exhibited a mixed autoimmune-autoinflammatory phenotype. Autoinflammation-predominant disease was most common in the youngest age group (p = 0.029) and in the Chinese group (p < 0.0001). A total of 89 TNFAIP3 pathogenic mutations were identified, including novel variants resulting in protein truncation or heterozygous deletion. No clear association was found between clinical phenotype and genetic architecture. Anti-TNF and anti-IL-1 agents were effective in most patients (60% and 63.2% respectively), particularly in those with inflammatory arthritis or gastrointestinal ulcers. Two thirds of patients achieved complete remission at their last follow-up visit.

Conclusion: HA20 presents with highly variable phenotypes, including autoinflammation-predominant, autoimmune-predominant, and mixed phenotypes. Autoimmunity may become more common over time and have a lower incidence in individuals with specific ancestries, although these differences could still be related to ascertainment bias in specific age groups and/or countries. No definitive genotype-phenotype correlation was observed. Lastly, this comprehensive and systematic description of a large international cohort may suggest improved precision medicine strategies for the complex care of HA20 patients.ReferencesZhou Q, et al. Nat Genet. 2016.

Supporting image 1

Supporting image 2Genetic analysis of HA20 patients.

A. Genetic analysis of this cohort revealed 85 pathogenic variants in TNFAIP3. Gene variants in red and black font represented novel variants and reported variants, respectively.

B. Common variants identified in HA20 patients.


Disclosures: M. Carpio Tumba: None; T. He: National Natural Science Foundation of China, 5; J. Wang: China Postdoctoral Science Foundation, 5, National Natural Science Foundation of China, 5; E. Kairis: None; K. Goyette: None; A. Kethri: None; U. Karri: None; A. Towheed: None; J. Yang: Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties, 5; Q. Zhou: National Natural Science Foundation of China, 5; D. Schwartz: Eli Lilly, 5, Jeffrey Modell Foundation, 5, National Institutes of Health, 5, Samuel and Emma Winters Foundation, 5, Sobi, 1, 5.

To cite this abstract in AMA style:

Carpio Tumba M, He T, Wang J, Kairis E, Goyette K, Kethri A, Karri U, Towheed A, Yang J, Zhou Q, Schwartz D. The Largest International Cohort Study of HA20 Reveals Novel Genetic Architecture and Age-Dependent Phenotypic Evolution [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-largest-international-cohort-study-of-ha20-reveals-novel-genetic-architecture-and-age-dependent-phenotypic-evolution/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-largest-international-cohort-study-of-ha20-reveals-novel-genetic-architecture-and-age-dependent-phenotypic-evolution/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology